Related medicinesFollitropin alfaFollitropin betaCorifollitropin alfa
Where it comes from
- Made in
- Gonadotroph cells of the anterior pituitary
- Sent out by
- Slow GnRH pulses favour it; activin raises it, inhibin and oestrogen hold it down; highest in the early follicular phase
- Acts on
- Ovarian granulosa cells
- Testicular Sertoli cells
What it does
- Recruits a cohort of follicles each cycle and makes them produce oestrogen; the one most sensitive to it becomes dominant as FSH falls
- Supports sperm production through the Sertoli cells
- Rises steeply at menopause, the laboratory sign of it
In medicine
- Recombinant FSH (follitropin alfa and beta, and the weekly corifollitropin alfa) and urinary menotropins drive the multiple follicles of IVF and induce ovulation 4
- Measured for ovarian reserve, menopause, male infertility and pituitary disease
- Mutations of FSH or its receptor cause infertility; an overactive receptor causes ovarian hyperstimulation in pregnancy
Beyond the body’s own use
- Recombinant and urinary gonadotrophins were compared across 42 trials and 9,606 couples with no difference in live birth or hyperstimulation, so the choice turns on cost and convenience 1
- Corifollitropin alfa, a single injection covering the first week of stimulation, was approved in Europe on non-inferiority to daily follitropin beta rather than on any advantage in births 4
- Blocking FSH with an antibody turned white fat beige and reduced body fat in mice, which raised the idea of one treatment for the fat and bone changes of menopause 2
- The bone half of that was shown earlier with an antibody against the FSH beta subunit, also in mice; no anti-FSH antibody has entered a human trial 3
Sources
- van Wely et al., Recombinant versus urinary gonadotrophin for ovarian stimulation, Cochrane Database of Systematic Reviews 2011
- Liu et al., Blocking FSH induces thermogenic adipose tissue and reduces body fat, Nature 2017
- Zhu et al., Blocking antibody to the beta-subunit of FSH prevents bone loss, Proceedings of the National Academy of Sciences 2012
- EMA assessment report, Elonva
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.